A Phase 1b Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1b Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs CWP 291 (Primary) ; Cytarabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors JW Pharmaceutical
  • Most Recent Events

    • 06 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 21 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top